Assembly Bio prioritizes ABI-4334, pauses ABI-H3733 on chronic toxicology finding; Q4 2022 net loss $93.1M

ASSEMBLY BIOSCIENCES, INC.

Phase 1a for ABI-4334 complete for single-dose and 100mg multiple-dose; half-life supports once-daily dosing; 200mg data expected April.
Phase 1b for ABI-H3733: all 7 HBeAg-negative patients achieved HBV DNA below LLOQ by day 21; chronic toxicology in one species halted program.
Net loss $93.1M ($1.92/share) for FY2022 vs $129.9M ($3.00/share) in 2021; cash $91.6M as of Dec 31, 2022, funding into mid-2024.
Second development candidate nomination expected in 2023; IND/CTA for herpesvirus candidate ABI-5366 planned for first half 2024.
CEO Jason Okazaki appointed as previously reported; no new leadership change in this filing.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ASSEMBLY BIOSCIENCES, INC. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 22, 2023, Assembly Biosciences, Inc. (the "Company") issued a press release (the "Press Release") announcing its financial results for the quarter and year ended December 31, 2022 and recent corporate highlights.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-009175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.